CN109843287A - 大麻属组合物 - Google Patents
大麻属组合物 Download PDFInfo
- Publication number
- CN109843287A CN109843287A CN201780060688.4A CN201780060688A CN109843287A CN 109843287 A CN109843287 A CN 109843287A CN 201780060688 A CN201780060688 A CN 201780060688A CN 109843287 A CN109843287 A CN 109843287A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- extract
- amount
- cannabis
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000218236 Cannabis Species 0.000 title claims abstract 13
- 239000000203 mixture Substances 0.000 title description 30
- 239000000284 extract Substances 0.000 claims abstract description 133
- 150000003505 terpenes Chemical class 0.000 claims abstract description 115
- 235000007586 terpenes Nutrition 0.000 claims abstract description 102
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 61
- 208000019116 sleep disease Diseases 0.000 claims abstract description 37
- 208000022925 sleep disturbance Diseases 0.000 claims abstract description 34
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000003085 diluting agent Substances 0.000 claims abstract description 18
- 239000003937 drug carrier Substances 0.000 claims abstract description 17
- 235000001510 limonene Nutrition 0.000 claims abstract description 16
- 229940087305 limonene Drugs 0.000 claims abstract description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 15
- 239000002671 adjuvant Substances 0.000 claims abstract description 12
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 46
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 33
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 30
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 30
- 229950011318 cannabidiol Drugs 0.000 claims description 29
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 28
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 claims description 26
- 229960004242 dronabinol Drugs 0.000 claims description 25
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims description 24
- FQTLCLSUCSAZDY-UHFFFAOYSA-N (+) E(S) nerolidol Natural products CC(C)=CCCC(C)=CCCC(C)(O)C=C FQTLCLSUCSAZDY-UHFFFAOYSA-N 0.000 claims description 23
- FQTLCLSUCSAZDY-ATGUSINASA-N Nerolidol Chemical compound CC(C)=CCC\C(C)=C\CC[C@](C)(O)C=C FQTLCLSUCSAZDY-ATGUSINASA-N 0.000 claims description 22
- WASNIKZYIWZQIP-AWEZNQCLSA-N nerolidol Natural products CC(=CCCC(=CCC[C@@H](O)C=C)C)C WASNIKZYIWZQIP-AWEZNQCLSA-N 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 20
- 229930006722 beta-pinene Natural products 0.000 claims description 14
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 238000006356 dehydrogenation reaction Methods 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- HEVGGTGPGPKZHF-UHFFFAOYSA-N 1-(1,2-dimethyl-3-methylidenecyclopentyl)-4-methylbenzene Chemical compound CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims 1
- 240000004308 marijuana Species 0.000 description 106
- 239000011487 hemp Substances 0.000 description 28
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 28
- 244000025254 Cannabis sativa Species 0.000 description 27
- 235000009120 camo Nutrition 0.000 description 23
- 235000005607 chanvre indien Nutrition 0.000 description 23
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 22
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 22
- 239000003795 chemical substances by application Substances 0.000 description 22
- -1 cannboid Natural products 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 17
- 239000000470 constituent Substances 0.000 description 17
- 239000000341 volatile oil Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 14
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 12
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 12
- 239000002775 capsule Substances 0.000 description 12
- 229930007744 linalool Natural products 0.000 description 12
- 239000007788 liquid Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000003213 activating effect Effects 0.000 description 9
- 150000001336 alkenes Chemical class 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 8
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical group C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 8
- 229960003453 cannabinol Drugs 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000010603 pastilles Nutrition 0.000 description 7
- 230000007958 sleep Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 229940102223 injectable solution Drugs 0.000 description 6
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- SEEZIOZEUUMJME-FOWTUZBSSA-N cannabigerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-FOWTUZBSSA-N 0.000 description 5
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 description 5
- 229960005233 cineole Drugs 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 4
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-beta-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 4
- JSNRRGGBADWTMC-UHFFFAOYSA-N (6E)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene Chemical compound CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 description 4
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 description 4
- SEEZIOZEUUMJME-VBKFSLOCSA-N Cannabigerolic acid Natural products CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 description 4
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 4
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 4
- LHXDLQBQYFFVNW-UHFFFAOYSA-N Fenchone Chemical compound C1CC2(C)C(=O)C(C)(C)C1C2 LHXDLQBQYFFVNW-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 4
- QXACEHWTBCFNSA-UHFFFAOYSA-N cannabigerol Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-UHFFFAOYSA-N 0.000 description 4
- 229930003827 cannabinoid Natural products 0.000 description 4
- 239000003557 cannabinoid Substances 0.000 description 4
- NVEQFIOZRFFVFW-RGCMKSIDSA-N caryophyllene oxide Chemical compound C=C1CC[C@H]2O[C@]2(C)CC[C@H]2C(C)(C)C[C@@H]21 NVEQFIOZRFFVFW-RGCMKSIDSA-N 0.000 description 4
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 4
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229940023488 pill Drugs 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000005418 vegetable material Substances 0.000 description 4
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 4
- YOVSPTNQHMDJAG-QLFBSQMISA-N β-eudesmene Chemical compound C1CCC(=C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C YOVSPTNQHMDJAG-QLFBSQMISA-N 0.000 description 4
- OPFTUNCRGUEPRZ-UHFFFAOYSA-N (+)-beta-Elemen Natural products CC(=C)C1CCC(C)(C=C)C(C(C)=C)C1 OPFTUNCRGUEPRZ-UHFFFAOYSA-N 0.000 description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 3
- IAIHUHQCLTYTSF-UHFFFAOYSA-N 2,2,4-trimethylbicyclo[2.2.1]heptan-3-ol Chemical compound C1CC2(C)C(O)C(C)(C)C1C2 IAIHUHQCLTYTSF-UHFFFAOYSA-N 0.000 description 3
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 3
- 235000008697 Cannabis sativa Nutrition 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 3
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- WGTRJVCFDUCKCM-ASEORRQLSA-N Ledene Natural products C[C@@H]1[C@H]2[C@H]3C(C)(C)[C@@H]3CCC(C)=C2CC1 WGTRJVCFDUCKCM-ASEORRQLSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 244000178231 Rosmarinus officinalis Species 0.000 description 3
- 208000022841 Sleep Arousal disease Diseases 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- OZQAPQSEYFAMCY-UHFFFAOYSA-N alpha-selinene Natural products C1CC=C(C)C2CC(C(=C)C)CCC21C OZQAPQSEYFAMCY-UHFFFAOYSA-N 0.000 description 3
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 3
- 229940116229 borneol Drugs 0.000 description 3
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 description 3
- WGTRJVCFDUCKCM-UHFFFAOYSA-N ent-ledene Natural products C1CC2C(C)(C)C2C2C(C)CCC2=C1C WGTRJVCFDUCKCM-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 239000003186 pharmaceutical solution Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229940116411 terpineol Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- WGTRJVCFDUCKCM-FMKGYKFTSA-N viridiflorene Chemical compound C1C[C@H]2C(C)(C)[C@H]2[C@@H]2[C@H](C)CCC2=C1C WGTRJVCFDUCKCM-FMKGYKFTSA-N 0.000 description 3
- WGTRJVCFDUCKCM-SCUASFONSA-N viridiflorene Natural products C1C[C@@H]2C(C)(C)[C@H]2[C@@H]2[C@@H](C)CCC2=C1C WGTRJVCFDUCKCM-SCUASFONSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- LHXDLQBQYFFVNW-XCBNKYQSSA-N (+)-Fenchone Natural products C1C[C@]2(C)C(=O)C(C)(C)[C@H]1C2 LHXDLQBQYFFVNW-XCBNKYQSSA-N 0.000 description 2
- HICYDYJTCDBHMZ-UHFFFAOYSA-N (+)-alpha-Longipinen Natural products C12C3C(C)=CCC1C3(C)CCCC2(C)C HICYDYJTCDBHMZ-UHFFFAOYSA-N 0.000 description 2
- HICYDYJTCDBHMZ-COMQUAJESA-N (+)-alpha-longipinene Chemical compound CC1(C)CCC[C@]2(C)[C@]3([H])[C@@]1([H])[C@@]2([H])CC=C3C HICYDYJTCDBHMZ-COMQUAJESA-N 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- ITYNGVSTWVVPIC-DHGKCCLASA-N (-)-allo-Aromadendrene Chemical compound C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-DHGKCCLASA-N 0.000 description 2
- BAVONGHXFVOKBV-NXEZZACHSA-N (-)-cis-carveol Chemical compound CC(=C)[C@@H]1CC=C(C)[C@H](O)C1 BAVONGHXFVOKBV-NXEZZACHSA-N 0.000 description 2
- DZVXRFMREAADPP-YDYPAMBWSA-N (1r,3r)-4-methyl-1-propan-2-ylbicyclo[3.1.0]hexan-3-ol Chemical compound C([C@@H](O)C1C)[C@]2(C(C)C)C1C2 DZVXRFMREAADPP-YDYPAMBWSA-N 0.000 description 2
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- NHMKYUHMPXBMFI-SNVBAGLBSA-N (4s)-2-methyl-6-methylideneocta-2,7-dien-4-ol Chemical compound CC(C)=C[C@@H](O)CC(=C)C=C NHMKYUHMPXBMFI-SNVBAGLBSA-N 0.000 description 2
- TZFPIQSSTVIJTQ-HUUCEWRRSA-N (6ar,10ar)-3-butyl-1-hydroxy-6,6,9-trimethyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCC)C(C(O)=O)=C1O TZFPIQSSTVIJTQ-HUUCEWRRSA-N 0.000 description 2
- XCYJPXQACVEIOS-UHFFFAOYSA-N 1-isopropyl-3-methylbenzene Chemical compound CC(C)C1=CC=CC(C)=C1 XCYJPXQACVEIOS-UHFFFAOYSA-N 0.000 description 2
- QUYCDNSZSMEFBQ-UHFFFAOYSA-N 3-ethyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CC)C=C3OC(C)(C)C2=C1 QUYCDNSZSMEFBQ-UHFFFAOYSA-N 0.000 description 2
- MSTDXOZUKAQDRL-UHFFFAOYSA-N 4-Chromanone Chemical compound C1=CC=C2C(=O)CCOC2=C1 MSTDXOZUKAQDRL-UHFFFAOYSA-N 0.000 description 2
- WBRXESQKGXYDOL-DLBZAZTESA-N 5-butyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound OC1=CC(CCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WBRXESQKGXYDOL-DLBZAZTESA-N 0.000 description 2
- NHZMSIOYBVIOAF-UHFFFAOYSA-N 5-hydroxy-2,2-dimethyl-3-(3-oxobutyl)-7-pentyl-3h-chromen-4-one Chemical compound O=C1C(CCC(C)=O)C(C)(C)OC2=CC(CCCCC)=CC(O)=C21 NHZMSIOYBVIOAF-UHFFFAOYSA-N 0.000 description 2
- OIVPAQDCMDYIIL-UHFFFAOYSA-N 5-hydroxy-2-methyl-2-(4-methylpent-3-enyl)-7-propylchromene-6-carboxylic acid Chemical compound O1C(C)(CCC=C(C)C)C=CC2=C1C=C(CCC)C(C(O)=O)=C2O OIVPAQDCMDYIIL-UHFFFAOYSA-N 0.000 description 2
- NAGBBYZBIQVPIQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-prop-1-en-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)=C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C NAGBBYZBIQVPIQ-UHFFFAOYSA-N 0.000 description 2
- VNGQMWZHHNCMLQ-UHFFFAOYSA-N 6-methyl-3-pentyl-9-propan-2-yldibenzofuran-1-ol Chemical compound C1=CC(C(C)C)=C2C3=C(O)C=C(CCCCC)C=C3OC2=C1C VNGQMWZHHNCMLQ-UHFFFAOYSA-N 0.000 description 2
- NVEQFIOZRFFVFW-UHFFFAOYSA-N 9-epi-beta-caryophyllene oxide Natural products C=C1CCC2OC2(C)CCC2C(C)(C)CC21 NVEQFIOZRFFVFW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- ITYNGVSTWVVPIC-XGFWRYKXSA-N Alloaromadendrene Natural products C([C@@H]1[C@H]2C1(C)C)CC(=C)[C@@H]1[C@@H]2[C@H](C)CC1 ITYNGVSTWVVPIC-XGFWRYKXSA-N 0.000 description 2
- 241000208983 Arnica Species 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 235000006965 Commiphora myrrha Nutrition 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 2
- 239000004863 Frankincense Substances 0.000 description 2
- 239000005792 Geraniol Substances 0.000 description 2
- TWVJWDMOZJXUID-SDDRHHMPSA-N Guaiol Chemical compound C1([C@H](CC[C@H](C2)C(C)(C)O)C)=C2[C@@H](C)CC1 TWVJWDMOZJXUID-SDDRHHMPSA-N 0.000 description 2
- NHMKYUHMPXBMFI-UHFFFAOYSA-N Ipsdienol-d Natural products CC(C)=CC(O)CC(=C)C=C NHMKYUHMPXBMFI-UHFFFAOYSA-N 0.000 description 2
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 2
- 244000178870 Lavandula angustifolia Species 0.000 description 2
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 2
- CKZXONNJVHXSQM-UHFFFAOYSA-N Ledol Natural products CC(C)C1CCC(C)(O)C2C3CC(C)CC123 CKZXONNJVHXSQM-UHFFFAOYSA-N 0.000 description 2
- 244000179970 Monarda didyma Species 0.000 description 2
- 235000010672 Monarda didyma Nutrition 0.000 description 2
- 235000007265 Myrrhis odorata Nutrition 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000000224 Night Terrors Diseases 0.000 description 2
- 208000006199 Parasomnias Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KXSDPILWMGFJMM-UHFFFAOYSA-N Sabinene hydrate Chemical compound CC1(O)CCC2(C(C)C)C1C2 KXSDPILWMGFJMM-UHFFFAOYSA-N 0.000 description 2
- 206010041009 Sleep talking Diseases 0.000 description 2
- 208000022249 Sleep-Wake Transition disease Diseases 0.000 description 2
- MOYAFQVGZZPNRA-UHFFFAOYSA-N Terpinolene Chemical compound CC(C)=C1CCC(C)=CC1 MOYAFQVGZZPNRA-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- HICYDYJTCDBHMZ-JLNYLFASSA-N alpha-longipinene Natural products CC=1[C@H]2[C@]3(C)[C@H]([C@H]2C(C)(C)CCC3)CC=1 HICYDYJTCDBHMZ-JLNYLFASSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- YOVSPTNQHMDJAG-UHFFFAOYSA-N beta-helmiscapene Natural products C1CCC(=C)C2CC(C(=C)C)CCC21C YOVSPTNQHMDJAG-UHFFFAOYSA-N 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 description 2
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- BQOFWKZOCNGFEC-UHFFFAOYSA-N carene Chemical compound C1C(C)=CCC2C(C)(C)C12 BQOFWKZOCNGFEC-UHFFFAOYSA-N 0.000 description 2
- RSYBQKUNBFFNDO-UHFFFAOYSA-N caryophyllene oxide Natural products CC1(C)CC2C(=C)CCC3OC3(C)CCC12C RSYBQKUNBFFNDO-UHFFFAOYSA-N 0.000 description 2
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- VLXDPFLIRFYIME-BTFPBAQTSA-N copaene Chemical compound C1C=C(C)[C@H]2[C@]3(C)CC[C@@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-BTFPBAQTSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- IEICDHBPEPUHOB-UHFFFAOYSA-N ent-beta-selinene Natural products C1CCC(=C)C2CC(C(C)C)CCC21C IEICDHBPEPUHOB-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 229940073505 ethyl vanillin Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 229930006735 fenchone Natural products 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002240 furans Chemical class 0.000 description 2
- WTRAORJBWZMQIV-UHFFFAOYSA-N gamma-bisabolene Natural products CC(C)CCCC(C)=C1CCC(C)=CC1 WTRAORJBWZMQIV-UHFFFAOYSA-N 0.000 description 2
- JBHJOURGKXURIW-UHFFFAOYSA-N gamma-cadinene Natural products CC(C)C1CCC(=C2CCC(=C)CC12)C JBHJOURGKXURIW-UHFFFAOYSA-N 0.000 description 2
- 150000002268 gamma-terpinene derivatives Chemical class 0.000 description 2
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 2
- 229940113087 geraniol Drugs 0.000 description 2
- TWVJWDMOZJXUID-QJPTWQEYSA-N guaiol Natural products OC(C)(C)[C@H]1CC=2[C@H](C)CCC=2[C@@H](C)CC1 TWVJWDMOZJXUID-QJPTWQEYSA-N 0.000 description 2
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- ZYTMANIQRDEHIO-KXUCPTDWSA-N isopulegol Chemical compound C[C@@H]1CC[C@@H](C(C)=C)[C@H](O)C1 ZYTMANIQRDEHIO-KXUCPTDWSA-N 0.000 description 2
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 2
- 239000001102 lavandula vera Substances 0.000 description 2
- 235000018219 lavender Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 150000002773 monoterpene derivatives Chemical class 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- WTEVQBCEXWBHNA-YFHOEESVSA-N neral Chemical compound CC(C)=CCC\C(C)=C/C=O WTEVQBCEXWBHNA-YFHOEESVSA-N 0.000 description 2
- YLYBTZIQSIBWLI-UHFFFAOYSA-N octyl acetate Chemical compound CCCCCCCCOC(C)=O YLYBTZIQSIBWLI-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000007965 phenolic acids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229930006696 sabinene Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229950010257 terpin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930010838 α-longipinene Natural products 0.000 description 2
- OGLDWXZKYODSOB-UHFFFAOYSA-N α-phellandrene Chemical compound CC(C)C1CC=C(C)C=C1 OGLDWXZKYODSOB-UHFFFAOYSA-N 0.000 description 2
- OZQAPQSEYFAMCY-QLFBSQMISA-N α-selinene Chemical compound C1CC=C(C)[C@@H]2C[C@H](C(=C)C)CC[C@]21C OZQAPQSEYFAMCY-QLFBSQMISA-N 0.000 description 2
- WTVHAMTYZJGJLJ-LSDHHAIUSA-N β-bisabolol Chemical compound CC(C)=CCC[C@H](C)[C@]1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-LSDHHAIUSA-N 0.000 description 2
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- WRHGORWNJGOVQY-KKUMJFAQSA-N (+)-gamma-cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(=C)[C@@H]21 WRHGORWNJGOVQY-KKUMJFAQSA-N 0.000 description 1
- NZGWDASTMWDZIW-MRVPVSSYSA-N (+)-pulegone Chemical compound C[C@@H]1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-MRVPVSSYSA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- XZRVRYFILCSYSP-OAHLLOKOSA-N (-)-beta-bisabolene Chemical compound CC(C)=CCCC(=C)[C@H]1CCC(C)=CC1 XZRVRYFILCSYSP-OAHLLOKOSA-N 0.000 description 1
- 229930006727 (-)-endo-fenchol Natural products 0.000 description 1
- BQSLMQNYHVFRDT-CABCVRRESA-N (-)-gamma-Elemene Natural products CC(C)=C1CC[C@](C)(C=C)[C@@H](C(C)=C)C1 BQSLMQNYHVFRDT-CABCVRRESA-N 0.000 description 1
- 239000001871 (1R,2R,5S)-5-methyl-2-prop-1-en-2-ylcyclohexan-1-ol Substances 0.000 description 1
- YMBFCQPIMVLNIU-GNXJLENFSA-N (1r,5s)-4,6-dimethyl-6-(4-methylpent-3-enyl)bicyclo[3.1.1]hept-3-ene Chemical group C1[C@@]2([H])C(C)=CC[C@@]1([H])C2(C)CCC=C(C)C YMBFCQPIMVLNIU-GNXJLENFSA-N 0.000 description 1
- FQTLCLSUCSAZDY-SDNWHVSQSA-N (6E)-nerolidol Chemical compound CC(C)=CCC\C(C)=C\CCC(C)(O)C=C FQTLCLSUCSAZDY-SDNWHVSQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VITZNDKHSIWPSR-HZPDHXFCSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-4-carboxylic acid Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=C(C(O)=O)C(CCCCC)=CC(O)=C3[C@@H]21 VITZNDKHSIWPSR-HZPDHXFCSA-N 0.000 description 1
- SSNHGLKFJISNTR-FWUPRJFYSA-N (6ar,10ar)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol;2-[(6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1[C@H](C(C)=C)CCC(C)=C1.C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 SSNHGLKFJISNTR-FWUPRJFYSA-N 0.000 description 1
- TZGCTXUTNDNTTE-DYZHCLJRSA-N (6ar,9s,10s,10ar)-6,6,9-trimethyl-3-pentyl-7,8,10,10a-tetrahydro-6ah-benzo[c]chromene-1,9,10-triol Chemical compound O[C@@H]1[C@@](C)(O)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 TZGCTXUTNDNTTE-DYZHCLJRSA-N 0.000 description 1
- FQTLCLSUCSAZDY-SZGZABIGSA-N (E)-Nerolidol Natural products CC(C)=CCC\C(C)=C/CC[C@@](C)(O)C=C FQTLCLSUCSAZDY-SZGZABIGSA-N 0.000 description 1
- 239000001707 (E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-ol Substances 0.000 description 1
- CXENHBSYCFFKJS-LOQWIJHWSA-N (E,E)-alpha-farnesene Natural products CC(C)=CCC\C(C)=C/C\C=C(\C)C=C CXENHBSYCFFKJS-LOQWIJHWSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- TYDDWHVJHGIJCW-OLKPEBQYSA-N (Z)-Ocimene Natural products O[C@@H](C(=C)C)C/C=C(/C=C)\C TYDDWHVJHGIJCW-OLKPEBQYSA-N 0.000 description 1
- JSNRRGGBADWTMC-NTCAYCPXSA-N (Z)-beta-Farnesene Natural products CC(C)=CCC\C(C)=C\CCC(=C)C=C JSNRRGGBADWTMC-NTCAYCPXSA-N 0.000 description 1
- IHPKGUQCSIINRJ-NTMALXAHSA-N (Z)-beta-ocimene Chemical compound CC(C)=CC\C=C(\C)C=C IHPKGUQCSIINRJ-NTMALXAHSA-N 0.000 description 1
- XBGUIVFBMBVUEG-CCEZHUSRSA-N (Z)-gamma-bisabolene Chemical compound CC(C)=CCC\C(C)=C1\CCC(C)=CC1 XBGUIVFBMBVUEG-CCEZHUSRSA-N 0.000 description 1
- UFLHIIWVXFIJGU-ARJAWSKDSA-N (Z)-hex-3-en-1-ol Chemical compound CC\C=C/CCO UFLHIIWVXFIJGU-ARJAWSKDSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- UEFGHYCIOXYTOG-UHFFFAOYSA-N 1-hydroxy-6,6,9-trimethyl-3-pentyl-8,9-dihydro-7h-benzo[c]chromen-10-one Chemical compound CC1(C)OC2=CC(CCCCC)=CC(O)=C2C2=C1CCC(C)C2=O UEFGHYCIOXYTOG-UHFFFAOYSA-N 0.000 description 1
- YEDIZIGYIMTZKP-UHFFFAOYSA-N 1-methoxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene Chemical compound C1=C(C)C=C2C3=C(OC)C=C(CCCCC)C=C3OC(C)(C)C2=C1 YEDIZIGYIMTZKP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 description 1
- COURSARJQZMTEZ-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-propylbenzene-1,3-diol Chemical compound OC1=CC(CCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C COURSARJQZMTEZ-UHFFFAOYSA-N 0.000 description 1
- RCSBILYQLVXLJG-UHFFFAOYSA-N 2-Propenyl hexanoate Chemical compound CCCCCC(=O)OCC=C RCSBILYQLVXLJG-UHFFFAOYSA-N 0.000 description 1
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 description 1
- AKRJXOYALOGLHQ-UHFFFAOYSA-N 2-methylheptan-4-one Chemical compound CCCC(=O)CC(C)C AKRJXOYALOGLHQ-UHFFFAOYSA-N 0.000 description 1
- GGVVJZIANMUEJO-UHFFFAOYSA-N 3-butyl-6,6,9-trimethylbenzo[c]chromen-1-ol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCC)C=C3OC(C)(C)C2=C1 GGVVJZIANMUEJO-UHFFFAOYSA-N 0.000 description 1
- IPGGELGANIXRSX-RBUKOAKNSA-N 3-methoxy-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylphenol Chemical compound COC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-RBUKOAKNSA-N 0.000 description 1
- NHIMSNHOEAVUKE-UHFFFAOYSA-N 3-methylheptan-4-one Chemical compound CCCC(=O)C(C)CC NHIMSNHOEAVUKE-UHFFFAOYSA-N 0.000 description 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical compound C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 description 1
- GKVOVXWEBSQJPA-UONOGXRCSA-N 5-methyl-2-[(1r,6r)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]benzene-1,3-diol Chemical compound CC(=C)[C@@H]1CCC(C)=C[C@H]1C1=C(O)C=C(C)C=C1O GKVOVXWEBSQJPA-UONOGXRCSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000722824 Ardisia crenata Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 description 1
- UVOLYTDXHDXWJU-NRFANRHFSA-N Cannabichromene Natural products C1=C[C@](C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-NRFANRHFSA-N 0.000 description 1
- IPGGELGANIXRSX-UHFFFAOYSA-N Cannabidiol monomethyl ether Natural products COC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 IPGGELGANIXRSX-UHFFFAOYSA-N 0.000 description 1
- WVOLTBSCXRRQFR-SJORKVTESA-N Cannabidiolic acid Natural products OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@@H]1[C@@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-SJORKVTESA-N 0.000 description 1
- ZLHQMHUXJUPEHK-UHFFFAOYSA-N Cannabivarin Natural products CCCc1cc(O)c2c(OC(C)(C)c3ccccc23)c1 ZLHQMHUXJUPEHK-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- VLXDPFLIRFYIME-GZBLMMOJSA-N Copaene Natural products C1C=C(C)[C@H]2[C@]3(C)CC[C@H](C(C)C)[C@H]2[C@@H]31 VLXDPFLIRFYIME-GZBLMMOJSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XURCUMFVQKJMJP-UHFFFAOYSA-N Dihydro-alpha-guaien Natural products C1C(C(C)C)CCC(C)C2=C1C(C)CC2 XURCUMFVQKJMJP-UHFFFAOYSA-N 0.000 description 1
- ORKZJYDOERTGKY-UHFFFAOYSA-N Dihydrocannabichromen Natural products C1CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 ORKZJYDOERTGKY-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- IAIHUHQCLTYTSF-MRTMQBJTSA-N Fenchyl alcohol Chemical compound C1C[C@]2(C)[C@H](O)C(C)(C)[C@H]1C2 IAIHUHQCLTYTSF-MRTMQBJTSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DJOWTWWHMWQATC-KYHIUUMWSA-N Karpoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1(O)C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C DJOWTWWHMWQATC-KYHIUUMWSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000378544 Melaleuca quinquenervia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 208000008705 Nocturnal Myoclonus Syndrome Diseases 0.000 description 1
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 description 1
- BLUHKGOSFDHHGX-UHFFFAOYSA-N Phytol Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)C=CO BLUHKGOSFDHHGX-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- NZGWDASTMWDZIW-UHFFFAOYSA-N Pulegone Natural products CC1CCC(=C(C)C)C(=O)C1 NZGWDASTMWDZIW-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 244000143590 Salvia chinensis Species 0.000 description 1
- 235000007154 Salvia chinensis Nutrition 0.000 description 1
- 235000005794 Salvia japonica Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 235000010086 Setaria viridis var. viridis Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000005439 Sleep paralysis Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 208000022890 Sleep-related eating disease Diseases 0.000 description 1
- 206010041235 Snoring Diseases 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 description 1
- HNZBNQYXWOLKBA-UHFFFAOYSA-N Tetrahydrofarnesol Natural products CC(C)CCCC(C)CCCC(C)=CCO HNZBNQYXWOLKBA-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BOTWFXYSPFMFNR-OALUTQOASA-N all-rac-phytol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)=CCO BOTWFXYSPFMFNR-OALUTQOASA-N 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- QMAYBMKBYCGXDH-SOUVJXGZSA-N alpha-Cadinene Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CC=C(C)[C@@H]21 QMAYBMKBYCGXDH-SOUVJXGZSA-N 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- ADIDQIZBYUABQK-UHFFFAOYSA-N alpha-Guaiene Natural products C1C(C(C)=C)CCC(C)C2=C1C(C)CC2 ADIDQIZBYUABQK-UHFFFAOYSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- QMAYBMKBYCGXDH-UHFFFAOYSA-N alpha-amorphene Natural products C1CC(C)=CC2C(C(C)C)CC=C(C)C21 QMAYBMKBYCGXDH-UHFFFAOYSA-N 0.000 description 1
- QMAYBMKBYCGXDH-KKUMJFAQSA-N alpha-cadinene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CC=C(C)[C@@H]21 QMAYBMKBYCGXDH-KKUMJFAQSA-N 0.000 description 1
- PFXFABJPDNHACA-UHFFFAOYSA-N alpha-copaene Natural products CC(C)C1C2CC(=CCC2C3(C)CC13)C PFXFABJPDNHACA-UHFFFAOYSA-N 0.000 description 1
- QDUJKDRUFBJYSQ-UHFFFAOYSA-N alpha-elemene Natural products CC(C)C1=CC(=C(C)C)CCC1(C)C=C QDUJKDRUFBJYSQ-UHFFFAOYSA-N 0.000 description 1
- IPZIYGAXCZTOMH-UHFFFAOYSA-N alpha-eudesmol Natural products CC1=CCCC2CCC(CC12)C(C)(C)O IPZIYGAXCZTOMH-UHFFFAOYSA-N 0.000 description 1
- ADIDQIZBYUABQK-RWMBFGLXSA-N alpha-guaiene Chemical compound C1([C@H](CC[C@H](C2)C(C)=C)C)=C2[C@@H](C)CC1 ADIDQIZBYUABQK-RWMBFGLXSA-N 0.000 description 1
- PSVBPLKYDMHILE-UHFFFAOYSA-N alpha-humulene Natural products CC1=C/CC(C)(C)C=CCC=CCC1 PSVBPLKYDMHILE-UHFFFAOYSA-N 0.000 description 1
- OGLDWXZKYODSOB-SNVBAGLBSA-N alpha-phellandrene Natural products CC(C)[C@H]1CC=C(C)C=C1 OGLDWXZKYODSOB-SNVBAGLBSA-N 0.000 description 1
- 150000001388 alpha-terpinene derivatives Chemical class 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- USMNOWBWPHYOEA-UHFFFAOYSA-N alpha-thujone Natural products CC1C(=O)CC2(C(C)C)C1C2 USMNOWBWPHYOEA-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- XZRVRYFILCSYSP-UHFFFAOYSA-N beta-Bisabolene Natural products CC(C)=CCCC(=C)C1CCC(C)=CC1 XZRVRYFILCSYSP-UHFFFAOYSA-N 0.000 description 1
- 229940074775 beta-bisabolol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000213578 camo Species 0.000 description 1
- 229930192457 cannabichromanone Natural products 0.000 description 1
- CSSYBWPIBDITMG-UHFFFAOYSA-N cannabicoumaronone Chemical compound O1C(C)(C)C(CCC(C)=O)C2=COC3=CC(CCCCC)=CC1=C32 CSSYBWPIBDITMG-UHFFFAOYSA-N 0.000 description 1
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 1
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 description 1
- 229930006737 car-3-ene Natural products 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229930007796 carene Natural products 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 1
- KXSDPILWMGFJMM-GUBZILKMSA-N cis-sabinene hydrate Natural products C([C@@]1(O)C)C[C@]2(C(C)C)[C@H]1C2 KXSDPILWMGFJMM-GUBZILKMSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- YOCDGWMCBBMMGJ-UHFFFAOYSA-N delta-cadinene Natural products C1C=C(C)CC2C(C(C)C)CCC(=C)C21 YOCDGWMCBBMMGJ-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002621 endocannabinoid Substances 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 229940093503 ethyl maltol Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- BAVONGHXFVOKBV-UHFFFAOYSA-N exo-carveol Natural products CC(=C)C1CC=C(C)C(O)C1 BAVONGHXFVOKBV-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WRHGORWNJGOVQY-RRFJBIMHSA-N gamma-Muurolene Natural products C1CC(C)=C[C@@H]2[C@H](C(C)C)CCC(=C)[C@H]21 WRHGORWNJGOVQY-RRFJBIMHSA-N 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- NGIVKZGKEPRIGG-CQSZACIVSA-N gamma-curcumene Chemical compound CC(C)=CCC[C@@H](C)C1=CC=C(C)CC1 NGIVKZGKEPRIGG-CQSZACIVSA-N 0.000 description 1
- NGIVKZGKEPRIGG-UHFFFAOYSA-N gamma-curcumene Natural products CC(C)=CCCC(C)C1=CC=C(C)CC1 NGIVKZGKEPRIGG-UHFFFAOYSA-N 0.000 description 1
- BQSLMQNYHVFRDT-LSDHHAIUSA-N gamma-elemene Chemical compound CC(C)=C1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 BQSLMQNYHVFRDT-LSDHHAIUSA-N 0.000 description 1
- RVOXATXFYDNXRE-UHFFFAOYSA-N gamma-elemene Natural products CC(=C1CCC(C)(C(C1)C(=C)C)C(=C)C)C RVOXATXFYDNXRE-UHFFFAOYSA-N 0.000 description 1
- WRHGORWNJGOVQY-ZNMIVQPWSA-N gamma-muurolene Chemical compound C1CC(C)=C[C@H]2[C@H](C(C)C)CCC(=C)[C@H]21 WRHGORWNJGOVQY-ZNMIVQPWSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 244000230342 green foxtail Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000010460 hemp oil Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000033923 irregular sleep wake type circadian rhythm sleep disease Diseases 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 229940095045 isopulegol Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- ZYTMANIQRDEHIO-UHFFFAOYSA-N neo-Isopulegol Natural products CC1CCC(C(C)=C)C(O)C1 ZYTMANIQRDEHIO-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000010461 other edible oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229930007459 p-menth-8-en-3-one Natural products 0.000 description 1
- 229930006948 p-menthane-3,8-diol Natural products 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 208000023515 periodic limb movement disease Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- BOTWFXYSPFMFNR-PYDDKJGSSA-N phytol Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC\C(C)=C\CO BOTWFXYSPFMFNR-PYDDKJGSSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- VPQBJIRQUUEAFC-UHFFFAOYSA-N selinene Natural products C1CC=C(C)C2CC(C(C)C)CCC21C VPQBJIRQUUEAFC-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- RBNWAMSGVWEHFP-WAAGHKOSSA-N terpin Chemical compound CC(C)(O)[C@H]1CC[C@@](C)(O)CC1 RBNWAMSGVWEHFP-WAAGHKOSSA-N 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- QHCQSGYWGBDSIY-HZPDHXFCSA-N tetrahydrocannabinol-c4 Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCC)=CC(O)=C3[C@@H]21 QHCQSGYWGBDSIY-HZPDHXFCSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- XJPBRODHZKDRCB-UHFFFAOYSA-N trans-alpha-ocimene Natural products CC(=C)CCC=C(C)C=C XJPBRODHZKDRCB-UHFFFAOYSA-N 0.000 description 1
- ZLWGOLLBNDIBMM-UHFFFAOYSA-N trans-nerolidol Natural products CC(C)C(=C)C(O)CCC=C(/C)CCC=C(C)C ZLWGOLLBNDIBMM-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- FCSRUSQUAVXUKK-VNHYZAJKSA-N α-Eudesmol Chemical compound C1C[C@@H](C(C)(C)O)C[C@H]2C(C)=CCC[C@@]21C FCSRUSQUAVXUKK-VNHYZAJKSA-N 0.000 description 1
- 229930000038 α-guaiene Natural products 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 229930000053 β-bisabolol Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种用于治疗睡眠障碍的方法。优选地,本发明涉及一种用于治疗睡眠障碍的方法,所述方法包括施用药物组合物的步骤,所述药物组合物包含大麻属(Cannabis)提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合,所述大麻属提取物包含萜烯级分,所述萜烯级分包含按萜烯级分的重量计至少约5.4%的量的柠檬烯。
Description
领域
本发明涉及一种用于治疗睡眠障碍的方法。本发明还涉及包含来自大麻属(Cannabis)植物的提取物的药物组合物及其在治疗睡眠障碍中的用途。
背景
大麻属的生物活性是众所周知的,并已促使其成为一种“娱乐性”药物。然而,随着一类大麻素(CB)受体的发现,以及管制大麻使用的法律的放松-在一些合法化司法管辖区(jurisdictions decriminalisation)-现在存在探索大麻属作为新治疗剂(therapeutics)来源的潜力的机会。
也存在越来越多的罹患慢性疾病(诸如睡眠障碍)的、寻求天然疗法作为替代或补充疗法的患者。
因此,对开发至少部分来源于天然来源的、用于睡眠障碍的新疗法存在持续需求。
概述
本发明提供了一种用于治疗睡眠障碍的方法,所述方法包括向有相应需要的患者施用有效量的包含大麻属提取物的药物组合物。因此,还提供了包含大麻属提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合的药物组合物。
大麻属提取物包含大麻素级分和萜烯级分。大麻素级分通常包含作为主要大麻素的Δ9-四氢大麻酚(THC)或大麻二酚(CDB)。大麻素级分还可以包含一种或更多种选自脱氢大麻二酚(CBN)和Δ9-四氢次大麻酚(THCV)的另外的大麻素。萜烯级分通常包含β-月桂烯。萜烯级分还可以包含芳樟醇、橙花叔醇和柠檬烯中的一种或更多种。当存在时,柠檬烯可以以按萜烯级分的重量计至少5.4%的量存在。
在一个方面,提供了一种药物组合物,所述药物组合物包含大麻属提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合,所述大麻属提取物包含萜烯级分,所述萜烯级分包含按萜烯级分的重量计至少约5.4%的量的柠檬烯。
优选地,大麻属提取物包含Δ9-四氢大麻酚(THC)、大麻二酚(CDB)、脱氢大麻二酚(Cannabinodiol)(CBN)和β-月桂烯。
在本发明的一个实施方案中,药物组合物中的THC是按提取物的重量计0%至90%的量。
在本发明的一些实施方案中,药物组合物还包含β-石竹烯、芳樟醇、橙花叔醇1、罗勒烯、α-蒎烯和β-蒎烯中的一种或更多种。
在本发明的一个实施方案中,药物组合物中的THC是按提取物的重量计0%至90%的量。
在本发明的一些实施方案中,药物组合物还包含β-石竹烯、芳樟醇、橙花叔醇1、罗勒烯、α-蒎烯和β-蒎烯中的一种或更多种。
在另外的方面,提供了大麻属提取物在制备用于治疗睡眠障碍的药物中的用途。
在又另一个方面,提供了一种用于治疗睡眠障碍的药物组合物,其中所述药物组合物包含大麻属提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
在一个实施方案中,本发明提供了包含含有萜烯级分的大麻属提取物的药物组合物,其中所述组合物包含:
(i)按大麻属提取物的重量计0%至90%的量的Δ9-四氢大麻酚(THC);
(ii)按大麻属提取物的重量计0%至20%的量的大麻二酚(CBD);
(iii)按大麻属提取物的重量计0%至20%的量的脱氢大麻二酚(CBN);
(iv)按大麻属提取物的重量计0%至20%的量的β-月桂烯;
以及
(v)按萜烯级分的重量计至少约5.4%的量的柠檬烯;
其中所述药物组合物任选地包含一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
在一个实施方案中,本发明提供了一种用于治疗睡眠障碍的药物组合物,所述药物组合物包含含有萜烯级分的大麻属提取物,其中所述组合物包含:
(i)按大麻属提取物的重量计0%至90%的量的Δ9-四氢大麻酚(THC);
(ii)按大麻属提取物的重量计0%至20%的量的大麻二酚(CBD);
(iii)按大麻属提取物的重量计0%至20%的量的脱氢大麻二酚(CBN);和
(iv)按大麻属提取物的重量计0%至20%的量的β-月桂烯;
以及
(v)按萜烯级分的重量计至少约5.4%的量的柠檬烯;
其中所述药物组合物任选地包含一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
在另外的方面,提供了大麻属提取物在制备用于治疗睡眠障碍的药物中的用途。
在又另一个方面,提供了一种用于治疗睡眠障碍的药物组合物,其中所述药物组合物包含大麻属提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
在另外的方面,本发明提供了一种口服药物溶液,所述口服药物溶液包含含有萜烯级分的大麻属提取物,其中所述组合物包含:
(i)按大麻属提取物的重量计0%至90%的量的Δ9-四氢大麻酚(THC);
(ii)按大麻属提取物的重量计0%至20%的量的大麻二酚(CBD);
(iii)按大麻属提取物的重量计0%至20%的量的脱氢大麻二酚(CBN);
(iv)按大麻属提取物的重量计0%至20%的量的β-月桂烯;
以及
(v)按萜烯级分的重量计至少约5.4%的量的柠檬烯;
其中所述药物组合物任选地包含一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
优选地,口服药物溶液呈舌下喷雾剂形式。
实施方案描述
本发明提供了一种药物组合物,所述药物组合物包含大麻属提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
大麻属植物产生各种各样的次级代谢物,包括大麻素、萜烯和类萜、甾醇、甘油三酯、烷烃、角鲨烯、生育酚、类胡萝卜素和生物碱。这些次级代谢物的混合物根据几个因素而不同,所述因素包括大麻属品种、提取的大麻属植物的部分、提取方法、提取物的加工和季节。
存在已根据两种不同的命名惯例进行描述的几个大麻属植物品种。这些惯例中的一种确认了大麻属植物三个不同的种,即大麻(Cannabis sativa Linnaeus)、印度大麻(Cannabis indica LAM.)和莠草大麻(Cannabis ruderalis)。另一种惯例将所有大麻属植物都确认为属于大麻物种,其中不同品种被分成几种亚种,包括:大麻sativa亚种和印度亚种(Cannabis sativa ssp.andssp.indica)。如本文使用的,术语“大麻属”是指任何和所有这些植物品种。
大麻属提取物可以通过本领域中已知的任何方法制备。提取物可以由包含大麻素、萜烯和类萜化合物的大麻属植物的任何部分形成。提取物可以通过将提取剂与叶、种子、毛状体、花、大麻属晶体(keif)、花苞残片(shake)、芽、茎或其组合接触而形成。在一些实施方案中,提取物由大麻属植物的花和花体残余形成。可以使用本领域已知的任何合适的提取剂,包括例如醇类(例如甲醇、乙醇、丙醇、丁醇、丙二醇等)、水、烃类(例如丁烷、己烷等)、油(例如橄榄油、植物油、精油等)、溶剂(例如乙酸乙酯、聚乙二醇等)或超临界流体(例如液态CO2)。提取剂可以在将大麻属提取物掺入药物组合物之前被完全或部分去除,或者提取剂可以作为载体被包含在药物组合物中。提取剂可以通过任选地在减压下加热提取物来去除。应当理解,一些易挥发性的植物代谢物(诸如萜烯)也可以用提取剂去除。因此,在一些实施方案中,去除提取剂可以富集提取物中的大麻素级分。在一些实施方案中,例如通过使提取物通过滤纸或细筛(例如具有5μm孔径的筛)过滤提取物以去除颗粒物。
在一些实施方案中,大麻属提取物通过对植物材料施加热和压力来形成。通常,在这些实施方案中,不需要提取剂。
在一些实施方案中,大麻属提取物是大麻属的油(Cannabis oil)。如本文使用的,“大麻属的油”是通过将大麻属植物的至少一部分与油接触而形成的提取物。提取性油可以任选地被去除。提取性油可以选自橄榄油、大麻油(hemp oil)、芝麻油、椰子油、植物油、菜籽油、葡萄籽油、杏仁油、中链甘油三酯(MCT)油和任何其他可食用油,或其组合。
如本文使用的术语“大麻素”涉及从大麻属植物中分离的或合成产生的具有涉及内源性大麻素系统(endocannabinoid system)的活性的任何大麻素。
术语“大麻素级分”用于描述大麻属提取物中存在的大麻素化合物的组合。
如本文使用的术语“萜烯”或“类萜”是指通常提供独特的气味的一类烃分子。萜烯衍生自具有分子式C5H8的异戊二烯单元。萜烯的基本分子式是异戊二烯单元的倍数,即(C5H8)n,其中n是连接的异戊二烯单元的数目。类萜是通常通过氧化过程在植物中被进一步代谢并且因此通常包含至少一个氧原子的萜烯化合物。
术语“萜烯级分”用于描述大麻属提取物中存在的萜烯和类萜化合物的组合。
发明人已经观察到当萜烯级分具有某些谱(profile),即提取物中存在某些比例的特定萜烯/类萜时,药物组合物的效力得到增强。认为,效力的增加可以是协同的(即非加和性的)。还认为萜烯级分中特定组分的存在可以增强患者对大麻素疗法的耐受性。
在一些实施方案中,大麻属提取物包含大量(例如按重量计大于50%)的大麻素级分,通常为THC。在一些实施方案中,大麻属提取物可以包含按大麻属提取物的重量计约50%至约99.999%,例如按大麻属提取物的重量计约55%至约99.999%、约60%至约99.999%、约70%至约99.999%、约80%至约99.999%、约90%至约99.999%、约90%至约99.99%、约90%至约99.9%、或约90%至约99.5%的量的大麻素级分。在一些实施方案中,大麻属提取物包含按重量计约0.001%至约50%的非大麻素,例如按重量计约0.001%至约20%、或按重量计约0.001%至约10%的非大麻素。
在一些实施方案中,大麻素级分按药物组合物的重量计约0.001至约60%,例如按药物组合物的重量计约5%至约55%或约10%至约50%存在。
在一些实施方案中,一种或更多种另外的化合物(例如大麻素、萜烯或类萜化合物)可以被添加至大麻属提取物。添加化合物可以是为了补偿大麻属植物中表达的某些化合物的相对量的天然变化。添加的化合物可以是所期望化合物的合成形式(syntheticversion),它们可以是从其他大麻属提取物中获得的纯化的化合物,或者它们可以通过混合两种或更多种大麻属提取物来添加。
迄今,在大麻属植物中已经鉴定出超过100种大麻素。这些大麻素的综合列表可以见于Handbook of Cannabis Roger Pertwee(编著)Oxford University Press(2014)(ISBN:9780199662685)中的Mahmoud A.El Sohly和Waseem Gul“Constituents ofCannabis Sativa.”。在大麻属植物中已经鉴定出的大麻素包括:大麻萜酚(E)-CBG-C5、大麻萜酚单甲醚(E)-CBGM-C5 A、大麻萜酚酸A(Z)-CBGA-C5 A、次大麻萜酚(Cannabigerovarin)(E)-CBGV-C3、大麻萜酚酸A(E)-CBGA-C5 A、大麻萜酚酸A单甲醚(E)-CBGAM-C5 A和次大麻萜酚酸A(E)-CBGVA-C3A;(±)-大麻色烯(Cannabichromene)CBC-C5、(±)-大麻色烯酸A CBCA-C5 A、(±)-次大麻色烯(Cannabivarichromene)、(±)-次大麻色酚(Cannabichromevarin)CBCV-C3、(±)-次大麻色酚酸(Cannabichromevarinic acid)ACBCVA-C3 A;(-)-大麻二酚CBD-C5、大麻二酚单甲醚CBDMC5、大麻二酚-C4 CBD-C4、(-)-次大麻二酚CBDV-C3、Cannabidiorcol CBD-Cl、大麻二酚酸CBDA-C5、次大麻二酚酸CBDVA-C3;脱氢大麻二酚CBNDC5、脱氢次大麻二酚(Cannabinodivarin)CBND-C3;Δ9-四氢大麻酚Δ9-THC-C5、Δ9-四氢大麻酚-C4Δ9-THCC4、Δ9-四氢次大麻酚Δ9-THCV-C3、Δ9-四氢cannabiorcolΔ9-THCO-Cl、Δ9-四氢大麻酚酸AΔ9-THCA-C5 A、Δ9-四氢大麻酚酸BΔ9-THCA-C5 B、Δ9-四氢大麻酚酸-C4 A和/或BΔ9-THCA-C4 A和/或B、Δ9-四氢次大麻酚酸AΔ9-THCVA-C3 A、Δ9-四氢cannabiorcolic acidA和/或BΔ9-THCOA-Cl A和/或B、(-)-Δ8-反式-(6aR,10aR)-Δ8-四氢大麻酚Δ8-THC-C5、(-)-Δ8-反式-(6aR,10aR)-四氢大麻酚酸AΔ8-THCA-C5 A、(-)-(6aS,10aR)-Δ9-四氢大麻酚(-)-顺式-Δ9-THC-C5;大麻酚CBN-C5、大麻酚-C4 CBN-C4、次大麻酚(Cannabivarin)CBN-C3、大麻酚C2 CBN-C2、大麻酚CBN-Cl、大麻酚酸A CBNA-C5 A、大麻酚甲醚CBNM-C5、(-)-(9R,10R)-反式-二羟基大麻酚(-)-反式-CBT-C5((-)-(9R,10R)-反式-大麻三醇(-)-反式-CBT-C5)、(+)-(9S,10S)-二羟基大麻酚(+)-反式-CBT-C5、(±)-(9R,10S/9S,10R)-二羟基大麻酚(±)-顺式-CBT-C5、(-)-(9R,10R)-反式-10-O-乙基-二羟基大麻酚(-)-反式-CBT-OEt-C5、(±)-(9R,10R/9S,10S)-二羟基大麻酚-C3(±)-反式-CBT-C3、8,9-二羟基-Δ6a(10a)-四氢大麻酚8,9-Di-OH-CBT-C5、大麻二酚酸A二羟基大麻酚酯CBDA-C59-OH-CBT-C5酯、(-)-(6aR,9S,10S,10aR)-9,10-二羟基-六氢大麻酚、Cannabiripsol、Cannabiripsol-C5、(-)-6a,7,10a-三羟基-Δ9-四氢大麻酚(-)-大麻四醇、10-氧代-Δ6a(10a)四氢大麻酚OTHC;(5aS,6S,9R,9aR)-大麻艾尔松((5aS,6S,9R,9aR)-Cannabielsoin)CBE-C5、(5aS,6S,9R,9aR)-C3-大麻艾尔松CBE-C3、(5aS,6S,9R,9aR)-大麻艾尔松酸A CBEA-C5 A、(5aS,6S,9R,9aR)-大麻艾尔松酸B CBEA-C5 B;(5aS,6S,9R,9aR)-C3-大麻艾尔松酸B CBEA-C3 B、大麻环醚萜酚-C3 OH-异-HHCV-C3、脱氢大麻呋喃(Dehydrocannabifuran)DCBF-C5、大麻呋喃(Cannabifuran)CBF-C5、(-)-Δ7-反式-(1R,3R,6R)-异四氢大麻酚、(±)-Δ7-1,2-顺式-(1R,3R,6S/1S,3S,6R)-异四氢次大麻酚,(-)-Δ7-反式-(1R,3R,6R)-异四氢次大麻酚;(±)-(laS,3aR,8bR,8cR)-大麻环酚CBL-C5、(±)-(1aS,3aR,8bR,8cR)-大麻环酚酸A CBLA-C5 A、(±)-(laS,3aR,8bR,8cR)-次大麻环酚CBLV-C3;大麻二吡喃环烷CBTC5;大麻苯并二氢吡喃-4-酮(Cannabichromanone)CBCN-C5、大麻苯并二氢吡喃-4-酮C3 CBCN-C3和大麻苯并呋喃酮(Cannabicoumaronone)CBCON-C5。
大麻属提取物可以包含按重量计50%-99%的主要大麻素。主要大麻素可以是Δ9-四氢大麻酚(THC)或大麻二酚(CBD)。在一些实施方案中,大麻属提取物包含按大麻素级分的重量计55%-95%的主要大麻素。通常,大麻属提取物还包含一种或更多种次级大麻素。THC或CBD也可以作为次级大麻素存在于大麻属提取物中。通常,每种次级大麻素以按大麻素级分的重量计0.001%至约30%的量存在。
提取物可以包含按提取物的重量计0%至90%,例如按提取物的重量计0.001%-90%或2%-85%的量的THC。当THC作为主要大麻素存在时,提取物可以包含按提取物的重量计40%-90%、50%-90%或55%-85%的量的THC。当THC作为次级大麻素存在时,提取物可以包含按提取物的重量计0.001%-20%,例如按提取物的重量计0.001%-15%或0.005%-10%的量的THC作为次级大麻素。
因此,在一些实施方案中,大麻属提取物包含按提取物的重量计0%-20%,例如按提取物的重量计0.001%-20%或0%-10%的大麻二酚(CBD)作为次级大麻素。
在一些实施方案中,大麻属提取物包含按提取物的重量计0%-20%,例如按提取物的重量计0.001%-20%或0%-10%的脱氢大麻二酚(CBN)。
在一些实施方案中,大麻属提取物包含按提取物的重量计0%-50%,例如按提取物的重量计0.001%-20%或0%-10%的Δ9-四氢次大麻酚(THCV)。
通常,除了THC和/或CBD之外,大麻属提取物还包含其他大麻素。这些大麻素包括Δ9-四氢大麻酚酸(THCA)、Δ9-四氢次大麻酚(THCV)、(-)-次大麻二酚(CBDV)、和大麻萜酚(CBG)。这些大麻素中的每一种可以以按组合物的重量计0.001%至30%的量存在。
在一些实施方案中,某些大麻素可以不存在,或者以检测不到的量(例如按分析物的重量计少于0.001%)存在。在一些实施方案中,大麻属提取物可以不包含以下大麻素中的一种或更多种:大麻二酚(CBD)、Δ9-四氢次大麻酚(THCV)、大麻二酚酸(CBDA)、大麻萜酚酸(CBGA)、脱氢大麻二酚(CBN)和次大麻二酚(CBDV)。
大麻属提取物包含非大麻素化合物,所述非大麻素化合物通常包含萜烯级分,即萜烯和类萜。在一些实施方案中,大麻属提取物包含按提取物的重量计少于50%,例如按提取物的重量计少于45%、40%、35%、30%、25%、20%、15%、10%、9%、8%、7%、6%、5%、4%、3%、2%或1%的量的萜烯级分。在一些实施方案中,大麻属提取物可以包含按提取物的重量计多于0.001%,例如提取物的总重量的多于0.001%、0.005%、0.01%、0.05%、0.1%、0.5%或1%的量的萜烯和类萜化合物。在一些实施方案中,大麻属提取物包含按组合物的重量计约0.001%至约50%,例如按组合物的重量计约0.001%至约20%、按组合物的重量计约0.001%至约10%、按组合物的重量计约0.001%至约6%或按组合物的重量计约0.001%至约5%的萜烯和类萜化合物。
通常,用于形成提取物的植物材料中的萜烯级分可以在萜烯级分中特定化合物的量和萜烯级分相对于其他组分的重量两方面具有与最终提取物中的萜烯级分谱(profile)不同的萜烯/类萜谱。例如,大麻属的花可以包含按重量计约20%的大麻素和按重量计约3%的萜烯。提取和浓缩(即去除提取剂)后,大麻素的量可以增加至按重量计约50%-90%的量,并且萜烯级分可以总计达到按大麻属提取物的重量计约0.1%-6%。这种典型情况显示,虽然当提取剂被去除时大麻素被浓缩,萜烯级分的相对量被减少,这可能是由于萜烯级分中存在的许多萜烯/类萜的挥发性。因此,大麻属提取物中存在的萜烯级分的谱与自然界中存在的萜烯级分的谱显著不同。
在大麻属提取物中还已经鉴定出多种萜烯和类萜,包括单萜烯、单类萜、倍半萜烯和倍半类萜。例如,在大麻提取物中已经鉴定出以下萜烯和类萜:别香树烯(alloaromadendrene)、己酸烯丙酯、苯甲醛、(Z)-α-顺式-佛手柑油烯((Z)-α-cis-bergamotene)、(Z)-α-反式-佛手柑油烯、β-红没药醇、表-α-红没药醇、β-红没药烯、冰片(borneol)(龙脑(camphol))、顺式-γ-红没药烯、乙酸冰片酯(乙酸龙脑酯(bomylacetate))、α-杜松烯、莰烯、莰酮、顺式-香芹醇、石竹烯(β-石竹烯)、α-蛇麻烯(α-石竹烯)、γ-杜松烯、δ-3-蒈烯、石竹烯氧化物、1,8-桉叶素、柠檬醛A、柠檬醛B、肉桂醛、α-古巴烯(aglaiene)、γ-姜黄烯、β-伞花烃(β-cymene)、β-榄香烯(β-elemene)、γ-榄香烯、癸二烯酸乙酯、乙基麦芽酚、丙酸乙酯、乙基香兰素(ethylvanillin)、桉油精(eucalyptol)、α-桉叶醇(α-eudesmol)、β-桉叶醇、γ-桉叶醇、丁香酚、顺式-β-金合欢烯((Z)-β-法尼烯((Z)-β-farnesene))、反式-α-法尼烯、反式-β-金合欢烯、反式-γ-红没药烯、葑酮(fenchone)、葑醇(norbomanol、β-葑醇)、香叶醇、α-愈创木烯、愈创木醇、邻氨基苯甲酸甲酯、水杨酸甲酯、2-甲基-4-庚酮、3-甲基-4-庚酮、乙酸己酯、齿小蠹二烯醇(ipsdienol)、乙酸异戊酯、lemonol、柠檬烯、d-柠檬烯(柠檬烯)、芳樟醇(里哪基醇(linalyl alcohol)、β-芳樟醇)、α-长叶蒎烯(α-longipinene)、薄荷醇、γ-木罗烯(γ-muurolene)、月桂烯(β-月桂烯)、橙花叔醇、反式-橙花叔醇、橙花醇、β-罗勒烯(顺式-罗勒烯)、乙酸辛酯、α-水芹烯、叶绿醇、α-蒎烯(2-蒎烯)、β-蒎烯、胡薄荷酮、桧烯(sabinene)、顺式-水合桧烯(顺式-侧柏醇(cis-thujanol))、β-蛇床烯(β-selinene)、α-蛇床烯、γ-萜品烯、异萜品(isoterpine)、萜品醇(terpineol)(α-萜品醇)、萜品醇-4-醇(terpineol-4-ol)、α-萜品烯(萜基烯(terpilene))、α-侧柏烯(α-thujene)(origanene)、香草醛、白千层烯烯(viridiflorene)(喇叭烯(ledene))、和α-ylange。
认为萜烯级分中特定萜烯/类萜化合物的存在与所用药物组合物的有益作用相关。
萜烯级分通常包含β-月桂烯。认为,β-月桂烯可以增强提取物中存在的大麻素的生物可利用度和/或可以有助于允许大麻素通过血脑屏障。β-月桂烯可以以按提取物的重量计约0%至约40%的量存在。在一些实施方案中,β-月桂烯以按萜烯级分的重量计约0%-40%,例如,萜烯级分的0.001%至约25%、5.1%至29%或约5.5%至约25%的量存在。
萜烯级分还可以包含芳樟醇、橙花叔醇和柠檬烯中的一种或更多种。
当存在时,柠檬烯可以以按萜烯级分的重量计至少约5.4%,例如,以按萜烯级分的重量计约5.5%至约50%或约5.5%至约20%的量存在。柠檬烯是具有分子式C10H16的环状单萜。存在许多不同的天然存在的异构体;然而,最常见的形式是右旋异构体,即D-柠檬烯。
芳樟醇是具有分子式C10H18O的类萜化合物,见于许多花卉和香料植物中。认为,当芳樟醇存在于大麻属提取物中时,是可以提供镇静作用的。在一些实施方案中,芳樟醇可以以按萜烯级分的重量计至少0.05%的量存在。在一些优选的实施方案中,芳樟醇以按萜烯级分的重量计至少5%的量存在。在其他实施方案中,芳樟醇以按萜烯级分的重量计0.05%至25%,例如按萜烯级分的重量计0.1%至20%的量存在。
橙花叔醇是具有分子式C15H26O的倍半类萜。橙花叔醇在自然界中以两种异构形式,即橙花叔醇1和橙花叔醇2存在,它们在中心烯烃周围的几何结构不同,即顺式或反式异构体。提取物可以包含按萜烯级分的重量计至少0.001%,例如按萜烯级分的重量计从0.01%至20%的量的橙花叔醇(即橙花叔醇1和橙花叔醇2两者)。通常,橙花叔醇1以相对于橙花叔醇2更大的量存在。在一些实施方案中,橙花叔醇1可以不存在(或以低于检测极限的量存在)。在一些实施方案中,橙花叔醇2可以不存在(或以低于检测极限的量存在)。在一些实施方案中,橙花叔醇1和橙花叔醇2不存在(或以低于检测极限的量存在)。橙花叔醇1可以以按萜烯级分的重量计至少约0.001%,例如按萜烯级分的重量计0.001%至20%或0.001%至15%的量存在于提取物中。橙花叔醇2可以以按萜烯级分的重量计至少约0.001%,例如按萜烯级分的重量计0.001%至20%或0.001%至15%的量存在于提取物中。
大麻属提取物还可以包含蒎烯(例如α-蒎烯和/或β-蒎烯)。蒎烯是具有分子式C10H16的双环单萜。发现蒎烯在自然界中呈两种异构形式:α-蒎烯和β-蒎烯。提取物可以包含按萜烯级分的重量计至少5%,例如以按萜烯级分的重量计至少6%、7%、8%、9%或10%的量的蒎烯(即α-蒎烯和β-蒎烯)。通常,β-蒎烯以大于α-蒎烯的量的量存在。然而,在一些实施方案中,相对于β-蒎烯α-蒎烯以更大的量存在。β-蒎烯与α-蒎烯的比率可以是约1:1、约2:1、约3:1、约4:1或约5:1。α-蒎烯可以以按萜烯级分的重量计至少约0.001%,例如按萜烯级分的重量计0.001%至30%或0.001%至20%的量存在于提取物中。β-蒎烯可以以按萜烯级分的重量计至少约0.001%,例如按萜烯级分的重量计0.001%至80%、10%至80%、20%至75%或40%至75%的量存在于提取物中。
萜烯级分还可以包含β-石竹烯。β-石竹烯可以以按萜烯级分的重量计至少0.001%,例如萜烯级分的0.001%至20%或0.001%至15%的量存在。
在一些实施方案中,提取物还包含蛇麻烯。认为,蛇麻烯可以增强提取物的镇静特性。蛇麻烯有时也被称为α-石竹烯。
大麻属提取物还可以包括罗勒烯。罗勒烯可以以按萜烯级分的重量计至少0.001%,例如按萜烯级分的重量计0.001%至20%或0.001%至5%的量存在。
在一些实施方案中,萜烯级分包括β-月桂烯、D-柠檬烯、β-石竹烯、芳樟醇、橙花叔醇1、罗勒烯、α-蒎烯和β-蒎烯。
在一些实施方案中,萜烯级分可以以按提取物的重量计0.001%至6%的量存在于组合物中,并且可以包含:
·按萜烯级分的重量计0%至40%的量的β-月桂烯;
·按萜烯级分的重量计0%至20%的量的β-石竹烯;
·按萜烯级分的重量计约5.5%至约50%的量的D-柠檬烯;
·按萜烯级分的重量计0%至20%的量的芳樟醇;
·按萜烯级分的重量计0%至80%的量的β-蒎烯;
·按萜烯级分的重量计0%至20%的量的α-蒎烯;
·按萜烯级分的重量计0%至20%的量的橙花叔醇1;
·按萜烯级分的重量计0%至20%的量的橙花叔醇2;以及
·按萜烯级分的重量计0%至20%的量的罗勒烯;
在一些实施方案中,特定的萜烯或类萜可以不存在,或者以检测不到的量(例如,按分析物的重量计少于0.001%)存在。在一些实施方案中,以下类萜或类萜中的一种或更多种不存在,或以检测不到的量存在:α-红没药醇、石竹烯氧化物、对伞花烃、莰烯、α-萜品烯、γ-萜品烯、δ-s-蒈烯、萜品油烯、异蒲勒醇、香叶醇和愈创木醇。
两种示例性药物组合物的大麻素级分和萜烯级分列于下表1和2中。大麻素的量按照通过高效液相色谱(HPLC)确定的被报告,并且萜烯的量按照通过气相色谱(GC)确定的被报告。应当理解,由于大麻属提取物来源于自然界,在一些情况下,每种组分的量可以相差+/-10%、+/-25%或+/-50%。对应于这些限值中的每一个的解释组合物中的潜在变化的量的范围也示于下表中。
表1–富含THC的药物组合物
注释:“ND”意指未检测到;“BDL”意指低于检测极限(例如,少于0.001mg/克)
表2–富含CBD的药物组合物
注释:“ND”意指未检测到;“BDL”意指低于检测极限(例如,少于0.001mg/克)
药物组合物还可以包含一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合。
载体、稀释剂、辅助剂和/或赋形剂是“药学上可接受的”,意味着它们与组合物的其他成分兼容,并且在施用时或施用后对受试者是无害的。
药物组合物可以通过例如根据诸如药物制剂领域那些熟知的技术(例如,参见Remington:The Science and Practice of Pharmacy,第21版,2005,LippincottWilliams&Wilkins)采用常规的固体或液体媒介物或稀释剂,以及适于所期望施用模式的类型的药物添加剂(例如赋形剂、粘合剂、防腐剂、稳定剂、调味剂等)来配制。药学上可接受的载体可以是被包括在美国药典/国家处方集(USP/NF)、英国药典(BP)、欧洲药典(EP)或日本药典(JP)中的任何载体。在一些实施方案中,载体、稀释剂、辅助剂和/或赋形剂可以是非天然的(例如合成产生的)。
药物组合物包括适于口服、直肠、鼻内、局部(包括口腔和舌下)、阴道或肠胃外(包括肌内、皮下和静脉内)施用的那些,或适于通过吸入或吹入施用的形式。
因此,大麻属提取物可以与常规辅助剂、载体、赋形剂或稀释剂一起被置于药物组合物及其单位剂量的形式中,并且以此类形式中可以被用作固体,诸如片剂或填充胶囊,或者液体,诸如溶液、悬浮液、乳液、酏剂或填充有它们的胶囊(全部用于口服使用),以栓剂的形式用于直肠施用;或者以无菌可注射溶液的形式用于肠胃外(包括皮下)使用。
此类药物组合物及其单位剂量形式可以以常规比例包含具有或不具有另外的活性化合物或原理的常规成分,并且此类单位剂型可以包含与待采用的期望每日剂量范围相称的任何合适的有效量的活性成分。
为了从本文描述的大麻属提取物制备药物组合物,药学上可接受的载体可以是固体或液体。固体形式制品包括粉末、片剂、丸剂、胶囊、扁囊剂(cachet)、栓剂和可分配的颗粒。固体载体可以是一种或更多种物质,所述一种或更多种物质也可以用作稀释剂、调味剂、增溶剂、润滑剂、悬浮剂、粘合剂、防腐剂、片剂崩解剂或包封材料。
合适的载体包括碳酸镁、硬脂酸镁、滑石、糖、乳糖、果胶、糊精、淀粉、明胶、黄芪胶、甲基纤维素、羧甲基纤维素钠、低熔点蜡、可可脂等。术语“制品(preparation)”意图包括活性化合物与作为提供胶囊的运载体的包封材料的制剂,在所述制剂中,有或没有载体,活性组分都被运载体所包围,因此运载体与活性成分相关联。同样,也包括扁囊剂和锭剂。片剂、粉末、胶囊、丸剂、扁囊剂和锭剂可以用作适于口服施用的固体形式。
液体形式制品包括溶液、分散体、悬浮液和乳液,例如水或水-丙二醇溶液。例如,肠胃外注射液体制品可以被制备为以聚乙二醇水溶液的溶液。
无菌液体形式的组合物包括无菌溶液、悬浮液、乳液、糖浆和酏剂。大麻属提取物可以悬浮于药学上可接受的载体,例如无菌水、无菌有机溶剂或两者的混合物中。
其他液体形式制品包括通过将大麻属提取物与一种或更多种天然来源的油(例如精油)或蜡组合制备的那些。“精油”是通过提取(例如蒸汽提取,或将植物材料与提取剂接触)或压榨获得的油,其主要包含植物材料的疏水且通常是芳香性的组分。合适的天然来源的油和蜡包括芝麻油、橄榄油、山金车精油(Arnica essential oil)、薰衣草精油、薰衣草穗精油(Lavender Spike essential oil)、乳香精油(Frankincense essential oil)、柠檬草精油、肉桂叶精油、迷迭香桉树脑精油(Rosemary Cineole essential oil)、迷迭香精油、佛手柑精油(Bergamot essential oil)、没药精油(Myrrh essential oil)、鼠尾草精油(Sage essential oil)、椰子油、蜂蜡和大麻油。
药物组合物可以被配制用于肠胃外施用(例如通过注射,例如弹丸注射(bolusinjection)或连续输注),并且可以以单位剂量形式存在于安瓿、预填充注射器、小体积输注容器或任选地具有添加的防腐剂的多剂量容器中。组合物可以采取在油性或水性媒介物中的悬浮液、溶液或乳液的此类形式,并且可以包含配制剂诸如悬浮剂、稳定剂和/或分散剂。可选地,活性成分可以呈粉末形式,通过无菌分离无菌固体或通过从溶液冻干获得,用于在使用之前用合适的媒介物,例如无菌、无热原水构制。
适于可注射使用的药物形式包括无菌可注射溶液或分散体,和用于临时制备无菌可注射溶液的无菌粉末。它们在制造和储存条件下应该是稳定的,并且可以保持抵抗氧化和微生物诸如细菌或真菌的污染作用。
用于可注射溶液或分散体的溶剂或分散介质可以包含任何常规溶剂或载体系统,并且可以包含例如水、乙醇、多元醇(例如甘油、丙二醇和液体聚乙二醇等)、其合适的混合物以及植物油。
适于可注射使用的药物形式可以通过任何合适的途径递送,包括静脉内、肌内、脑内、鞘内、硬膜外注射或输注。
无菌可注射溶液通过以下来制备:将所需量的大麻属提取物掺入根据需要具有诸如以上列举的那些的多种其他成分的合适的载体中,然后灭菌。通常,通过将各种无菌的活性成分掺入无菌媒介物中制备分散体,所述无菌媒介物包含基础分散介质和所需的来自以上列举的那些的其他成分。在用于制备无菌可注射溶液的无菌粉末的情况下,优选的制备方法是真空干燥或冷冻干燥活性成分加上任何另外的所需成分的先前无菌的悬浮液。
当活性成分被合适地保护时,它们可以例如通过惰性稀释剂或通过可吸收的可食用载体被口服施用,或者活性成分可以被包封在硬壳或软壳明胶胶囊中,或者活性成分可以被压制成片剂,或者活性成分可以被直接掺入饮食的食物中。对于口服治疗施用,活性成分可以与赋形剂混合并以可摄入片剂、含服片剂、锭剂、胶囊、酏剂、悬浮液、糖浆、薄片(wafer)等形式使用。
在治疗上有用的组合物中活性成分的量应该是足够的,该量将获得合适的剂量。
片剂、锭剂、丸剂、胶囊等也可以包含如下文所列组分:粘合剂诸如树胶(gum)、阿拉伯胶、玉米淀粉或明胶;赋形剂诸如磷酸氢钙(dicalcium phosphate);崩解剂诸如玉米淀粉、马铃薯淀粉、藻酸等;润滑剂诸如硬脂酸镁;和甜味剂诸如可以被添加的蔗糖、乳糖或糖精或调味剂诸如薄荷、冬青油或樱桃调味剂。当剂量单位形式是胶囊时,它除了上述类型的材料之外还可以包含液体载体。
多种其他材料可以作为包衣存在或以其他方式改变剂量单位的物理形式。例如,片剂、丸剂或胶囊可以用虫胶、糖或两者包衣。糖浆或酏剂可以包含活性化合物、作为甜味剂的蔗糖、作为防腐剂的对羟基苯甲酸甲酯和对羟基苯甲酸丙酯、染料和调味剂诸如樱桃或橙子味道。当然,在制备任何剂量单位形式中使用的任何材料应该是药学上纯的并且以所采用的量是基本上无毒的。另外,活性化合物可以被掺入到持续释放制品和制剂中,包括允许活性肽特异性递送至肠道特定区域的那些制品和制剂。
适于口服使用的水性溶液可以通过将活性组分溶解在水中并根据需要添加合适的着色剂、调味剂、稳定剂和增稠剂来制备。适于口服使用的水性悬浮液可以通过将细分的(finely divided)活性成分与粘性材料分散在水中来制备,粘性材料诸如天然或合成树胶、树脂、甲基纤维素、羧甲基纤维素钠或其他公知的悬浮剂。
药学上可接受的载体和/或稀释剂包括任何以及全部溶剂、分散介质、包衣、抗菌剂和抗真菌剂、等渗剂和吸收延迟剂等。
还包括意图在使用之前不久转化为用于口服施用的液体形式制剂的固体形式制品。此类液体形式包括溶液、悬浮液和乳液。除了活性组分之外,这些制剂还可以包含着色剂、调味剂、稳定剂、缓冲剂、人工和天然甜味剂、分散剂、增稠剂、增溶剂等。
用于向表皮的局部施用,活性成分可以被配制为软膏、乳膏或乳液,或作为透皮贴剂。软膏和乳膏可以例如用水性或油性基底配制并添加合适的增稠剂和/或胶凝剂。乳液可以用水性或油性基底配制并且通常还会包含一种或更多种乳化剂、稳定剂、分散剂、悬浮剂、增稠剂或着色剂。
适于在口中局部施用的制剂包括包含在调味基底(通常为蔗糖和阿拉伯树胶(acacia)或黄芪胶)中的活性剂的锭剂;包含在惰性基底诸如明胶和甘油或蔗糖和阿拉伯胶中的活性成分的笔剂(pastille);以及包含在合适的液体载体中的活性成分的口腔清洁剂。
溶液或悬浮液通过常规手段例如通过滴管、移液器或喷雾器直接应用于鼻腔。制剂可以以单剂量或多剂量形式提供。在滴管或移液器的后一种情况下,这可以通过患者施用适当的预定体积的溶液或悬浮液来实现。
在喷雾器的情况下,这可以通过例如计量式雾化喷雾泵(metering atomisingspray pump)来实现。为了改善鼻内递送和保留,根据本发明的化合物可以用环糊精包封,或者用预期会增强鼻粘膜递送和保留的其他剂配制。
对呼吸道的施用也可以通过气雾剂制剂的方式来实现,其中活性成分以具有合适的喷射剂的加压包装提供,所述喷射剂为诸如氯氟烃(CFC),例如二氯二氟甲烷、三氯氟甲烷或二氯四氟乙烷、二氧化碳或其他合适的气体。
气雾剂也可以方便地包含表面活性剂诸如卵磷脂。药物的剂量可以通过提供计量阀来控制。
可选地,活性成分可以以干燥粉末,例如化合物在合适的粉末基底诸如乳糖、淀粉、淀粉衍生物诸如羟丙基甲基纤维素和聚乙烯吡咯烷酮(PVP)中的粉末混合物的形式提供。方便地,粉末载体可以在鼻腔中形成凝胶。粉末组合物可以以单位剂量形式存在于例如明胶或泡罩包装的胶囊或药筒(cartridge)中,粉末可以通过吸入器从其中被施用。
在意图用于向呼吸道施用的制剂,包括鼻内制剂中,化合物通常会具有例如5微米至10微米或更小数量级的小粒径。此类粒径可以通过本领域已知的方法,例如通过微粉化获得。
当需要时,可以采用适于给予活性成分持续释放的制剂。
药物制品优选地呈单位剂型。以此类形式,制品被细分为包含适当量的活性组分的单位剂量。单位剂型可以是包装的制品,该包装包含独立的量的制品,诸如包装于小瓶或安瓿中的片剂、胶囊和粉末。此外,单位剂型本身可以是胶囊、片剂、扁囊剂或锭剂,或者其可以是包装形式的适当数目的这些中的任何。
为了容易施用和剂量的一致性,配制剂量单位形式的肠胃外组合物是特别有利的。如本文使用的剂量单位形式是指适于作为待治疗的受试者的单一剂量的物理上的独立的单位;每个单位包含与所需药物载体缔合的、经计算以产生所期望的治疗作用的预定量的活性材料。剂量单位形式的规格由以下决定并直接依赖于:(a)活性材料的独特特征和待实现的特定治疗作用,以及(b)将此类活性材料配制用于治疗患有身体健康受损的疾病状况的活受试者中的HCV病毒感染的技术中固有的局限性。
本文还描述了不含载体的组合物,其中组合物呈单位剂型。因此,还提供了包含大麻属提取物的药物。
在一些实施方案中,药物组合物还包含除了大麻属提取物之外的活性剂。可以使用任何合适的活性剂,条件是当被组合时活性剂和/或大麻属提取物的活性不被减弱。
治疗方法
在另一个方面,还提供了一种用于治疗睡眠障碍的方法。该方法包括向有相应需要的患者施用有效量的本文描述的药物组合物。
药物组合物可以用于治疗睡眠障碍。睡眠障碍被描述睡眠障碍的国际分类(theInternational Classification of Sleep Disorders)(ICDS)中。ICDS-3于2014年公布,并将睡眠障碍表征为属于以下类别之一:(1)失眠;(2)睡眠相关呼吸障碍;(3)过度嗜睡的中枢障碍;(3)昼夜节律睡眠-觉醒障碍;(4)异态睡眠;(5)睡眠相关运动障碍。因此,待通过药物组合物治疗的睡眠障碍可以包括来自以下类别的任何睡眠障碍:(1)失眠;(2)睡眠相关呼吸障碍;(3)过度嗜睡的中枢障碍;(3)昼夜节律睡眠-觉醒障碍;(4)异态睡眠;(5)睡眠相关运动障碍。特别地,所述药物组合物可以有效治疗选自以下的睡眠障碍:失眠、发作性睡病、睡眠多度、睡眠呼吸暂停、周期性肢体运动障碍、不宁腿综合征、夜间进食(饮酒)综合征(nocturnal eating(drinking)syndrome)、飞行时差(jet lag)、轮班工作睡眠障碍(shift work sleep disorder)、不规律的睡-醒型态(irregular sleep-wake pattern)、觉醒混淆、梦游、夜惊(sleep terrors)、梦语症(sleep talking)、梦魇、睡眠性麻痹、REM睡眠行为障碍、打鼾、昏睡病、与其他疾病或状况相关的睡眠障碍或任何其他睡眠障碍。
“有效量”意指当向患者施用时提供一定量的药物以实现一种作用的足够的量。在治疗方法的情况下,这种作用可以是对睡眠障碍的治疗。因此,“有效量”可以是“治疗有效量”。“治疗有效量”意指当向患者施用时提供一定量的药物以治疗疾病或疾病的症状的足够的量。
如本文使用的,术语“治疗(treating)”、“治疗(treatment)”、“治疗(treat)”等意指影响受试者、组织或细胞以获得期望的药学的和/或生理学的作用。在完全或部分预防或减少疾病或相关症状的严重程度方面,该作用可以是预防性的,和/或在疾病的部分或完全治愈方面,该作用可以是治疗性的。因此,提及“治疗”睡眠障碍包括:(a)协助患者入睡;(b)在已经实现睡眠后,协助患者保持睡眠;(c)减轻或改善睡眠障碍的影响,例如在非睡眠期间增强清醒感;或(d)预防睡眠障碍在易患睡眠障碍或处于睡眠障碍风险的受试者中发生,因此睡眠障碍在受试者中不发展或发生,或以不太严重的形式发展。
该方法还可以包括施用除了大麻属提取物之外的活性剂。该活性剂可以与大麻属提取物同时或相继施用。相继意指大麻属提取物和其他活性剂中的每一种被单独施用,并且可以在不同的时间施用。通常,当大麻属提取物和其他活性剂被相继施用时,它们在彼此的24小时内,或者在彼此的12小时、8小时、6小时、5小时、4小时、3小时、2小时或1小时内被施用。大麻属提取物可以在其他活性剂之前或之后被施用。此外,大麻属提取物和其他活性剂的施用途径可以相同或不同。
在另一个方面,还提供了大麻属提取物在制备用于治疗睡眠障碍的药物中的用途。
还提供了一种试剂盒,所述试剂盒包括单独的部分:
(a)有效量的大麻属提取物;和
(b)药学上可接受的载体、稀释剂、辅助剂、赋形剂或其组合。
在一些实施方案中,试剂盒还包含含有(c)除了大麻属提取物之外的有效量的活性剂。
在另一个方面,提供了用于治疗睡眠障碍的药物组合物。药物组合物可以是任何以上描述的药物组合物,包括任何以上描述的组分的组合,条件是它包含具有指定萜烯级分的大麻属提取物。睡眠障碍可以是以上描述的那些中的任何一种。
实施例
将通过非限制性实施例的方式进一步描述本发明。本发明的领域的技术人员将理解,可以进行许多修改而不偏离本发明的精神和范围。
实施例1–大麻属提取物
描述了以下大麻属提取物:
AZ7–Ogre Shock植物的输注物(infusion)。
AZ8–ACDC植物的输注物。
注释:(1)使用HPLC分析检测大麻素,报告为0%的量表示该化合物未被检测到,或者以低于HPLC的检测极限的量存在;(2)使用GC分析检测萜烯,报告为0%的量表示该化合物未被检测到,或者以低于GC的检测极限的量存在;(3)为了考虑到自然变化(Naturalvariation),量在报告的值的+/-10%、+/-25%或+/-50%范围内。
除非上下文另有要求,本文提及的所有百分比都是按药物组合物的重量的百分比。
当用于描述值时,术语“约”优选地意指该值的±10%内的量。
除非本文另外指示或与上下文明显矛盾,否则在描述本发明和所附的权利要求书中的上下文的术语“一(a)”、“一(an)”、“和(and)”和/或“该(the)”以及相似的指示物,被解释为覆盖单数和复数两者。
应当理解,无论是在澳大利亚或任何其他国家,如果本文提及任何现有技术出版物,这种提及文献不构成对所述出版物形成本领域公知常识的部分的承认。
在所附的权利要求书中以及本发明的前述说明书中,除了上下文由于表述语言或必要的含义而另外要求时,词语“包含(comprise)”或变化形式诸如“包含(comprises)”或“包含(comprising)”以包括性意义被使用,即指定所陈述特征的存在但不排除另外特征在本发明不同实施方案中的存在或添加。
Claims (13)
1.一种药物组合物,所述药物组合物包含大麻属(Cannabis)提取物和任选地一种或更多种药学上可接受的载体、稀释剂、辅助剂、赋形剂或其任何组合,所述大麻属提取物包含萜烯级分,所述萜烯级分包含按所述萜烯级分的重量计至少约5.4%的量的柠檬烯。
2.如权利要求1所述的药物组合物,其中所述大麻属提取物包含Δ9-四氢大麻酚(THC)、大麻二酚(CDB)、脱氢大麻二酚(CBN)和β-月桂烯。
3.如权利要求1或2所述的药物组合物,所述药物组合物包含按所述提取物的重量计0%至90%的量的THC。
4.如权利要求1至3中任一项所述的药物组合物,所述药物组合物包含按所述提取物的重量计0%至20%的量的CBD。
5.如权利要求1至4中任一项所述的药物组合物,所述药物组合物包含按所述提取物的重量计0%至20%的量的CBN。
6.如权利要求1至5中任一项所述的药物组合物,所述药物组合物包含按所述提取物的重量计0%至20%的量的-β月桂烯。
7.如权利要求1至6中任一项所述的药物组合物,其中所述大麻属提取物为大麻属的油。
8.如权利要求1至7中任一项所述的药物组合物,所述大麻属提取物包含按重量计小于50%的量的萜烯级分。
9.如权利要求1至8中任一项所述的药物组合物,所述药物组合物还包含β-石竹烯、芳樟醇、橙花叔醇1、罗勒烯、α-蒎烯和β-蒎烯中的一种或更多种。
10.如权利要求1至9中任一项所述的药物组合物,所述药物组合物用于治疗睡眠障碍。
11.一种药物,所述药物包包含效量的权利要求1至10中任一项所述的药物组合物。
12.一种用于治疗睡眠障碍的方法,所述方法包括向有相应需要的患者施用有效量的权利要求1至10中任一项所述的药物组合物。
13.大麻属提取物在制备用于治疗睡眠障碍的药物中的用途,其中所述大麻属提取物包含萜烯级分,所述萜烯级分包含按所述萜烯级分的重量计至少约5.4%的量的柠檬烯。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662370304P | 2016-08-03 | 2016-08-03 | |
US62/370,304 | 2016-08-03 | ||
PCT/AU2017/050814 WO2018023163A1 (en) | 2016-08-03 | 2017-08-03 | Cannabis composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109843287A true CN109843287A (zh) | 2019-06-04 |
Family
ID=61072172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780060688.4A Pending CN109843287A (zh) | 2016-08-03 | 2017-08-03 | 大麻属组合物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US11779562B2 (zh) |
EP (1) | EP3493798A4 (zh) |
JP (1) | JP2019523283A (zh) |
KR (2) | KR20190035791A (zh) |
CN (1) | CN109843287A (zh) |
AU (4) | AU2017307643B2 (zh) |
BR (1) | BR112019001852A2 (zh) |
CA (1) | CA3031810A1 (zh) |
CL (1) | CL2019000270A1 (zh) |
CO (1) | CO2019001044A2 (zh) |
IL (2) | IL296008B1 (zh) |
MX (1) | MX2019001285A (zh) |
PE (1) | PE20200726A1 (zh) |
SG (1) | SG11201900665VA (zh) |
WO (1) | WO2018023163A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018023166A1 (en) | 2016-08-03 | 2018-02-08 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
MX2019011510A (es) * | 2017-03-30 | 2020-01-09 | Ojai Energetics Pbc | Metodos y composiciones para mejorar la salud. |
EP3641754A4 (en) * | 2017-06-19 | 2021-03-10 | Zelda Therapeutics Operations Pty Ltd | COMPOSITION AGAINST SLEEP APNEA AND RELATED TREATMENTS |
US11202771B2 (en) | 2018-01-31 | 2021-12-21 | Treehouse Biotech, Inc. | Hemp powder |
WO2019173242A1 (en) * | 2018-03-04 | 2019-09-12 | Cmg Partners, Inc. | Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same |
CA3103938A1 (en) * | 2018-06-15 | 2019-12-19 | California Cannabinoids | Compositions and methods for treatment of narcolepsy and related disorders |
EP3864000A4 (en) | 2018-10-10 | 2022-08-10 | Treehouse Biosciences, Inc. | CANNABIGEROL SYNTHESIS |
US20220160648A1 (en) * | 2019-02-13 | 2022-05-26 | Inspired Health Products, LLC | Composition Comprising Hydrolyzed Collagen and Cannabidiol and Use Thereof |
US11554098B2 (en) | 2019-05-03 | 2023-01-17 | HFL Partners, LLC | Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing |
US20230000935A1 (en) * | 2021-07-03 | 2023-01-05 | Joseph Anthony Bidwell | Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869356A (zh) * | 2010-03-12 | 2013-01-09 | Gw药品有限公司 | 治疗癌症中的植物大麻素 |
WO2014145490A2 (en) * | 2013-03-15 | 2014-09-18 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2400320B (en) | 2001-05-04 | 2005-06-08 | Gw Pharma Ltd | Cannabinoid-rich extracts |
JP4411117B2 (ja) * | 2004-03-25 | 2010-02-10 | エスエス製薬株式会社 | 睡眠改善医薬組成物 |
GB2418612A (en) | 2004-10-01 | 2006-04-05 | Gw Pharma Ltd | Inhibition of tumour cell migration with cannabinoids |
JP2007246428A (ja) * | 2006-03-15 | 2007-09-27 | Nature Technology Inc | 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法 |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
KR20110120153A (ko) * | 2010-04-28 | 2011-11-03 | 고려대학교 산학협력단 | 리모넨을 함유하는 아데노신 A2a 수용체 작용제 |
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
GB2496688B (en) | 2011-11-21 | 2016-06-29 | Gw Pharma Ltd | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases |
US20150126754A1 (en) | 2012-05-03 | 2015-05-07 | Echo Pharmaceuticals B.V. | Cannabis plant isolate comprising delta-9-tetrahydrocannabinol and a method for preparing such an isolate |
WO2014100231A1 (en) | 2012-12-18 | 2014-06-26 | Kotzker Consulting Llc | Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity |
US10792318B2 (en) | 2013-03-14 | 2020-10-06 | Sc Laboratories, Inc. | Bioactive concentrates and uses thereof |
US10265292B2 (en) | 2013-09-18 | 2019-04-23 | The Werc Shop, LLC | Terpene-based compositions, processes methodologies |
PT3062606T (pt) * | 2013-10-29 | 2019-07-17 | Biotech Inst Llc | Reprodução, produção, transformação e uso de canábis especial |
AU2014347807A1 (en) | 2013-10-31 | 2016-05-26 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
CA3111682A1 (en) * | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
WO2015200864A1 (en) | 2014-06-27 | 2015-12-30 | Crowley Kenton L | Buccal and sublingual cannabinoid formulations and method of making the same |
AU2015308546A1 (en) * | 2014-08-25 | 2017-04-13 | Clk Consult V/ Carsten Leonhard Knudsen | Device with compositions for delivery to the lungs, the oral mucosa and the brain |
CA2965493C (en) | 2014-10-21 | 2021-12-07 | United Cannabis Corp. | Cannabis extracts and methods of preparing and using same |
AU2015360349B2 (en) | 2014-12-12 | 2020-10-08 | Ojai Energetics Pbc | Microencapsulated cannabinoid compositions |
US10406186B2 (en) | 2015-01-31 | 2019-09-10 | Constance Therapeutics, Inc. | Cannabis oil extracts and compositions |
BR112017018316A2 (pt) | 2015-02-27 | 2018-04-17 | Ebbu Llc | composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral |
SG11201900596XA (en) | 2016-08-03 | 2019-02-27 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
WO2018023166A1 (en) | 2016-08-03 | 2018-02-08 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
-
2017
- 2017-08-03 KR KR1020197005589A patent/KR20190035791A/ko not_active Application Discontinuation
- 2017-08-03 CN CN201780060688.4A patent/CN109843287A/zh active Pending
- 2017-08-03 BR BR112019001852-2A patent/BR112019001852A2/pt active Search and Examination
- 2017-08-03 CA CA3031810A patent/CA3031810A1/en active Pending
- 2017-08-03 IL IL296008A patent/IL296008B1/en unknown
- 2017-08-03 AU AU2017307643A patent/AU2017307643B2/en active Active
- 2017-08-03 JP JP2019505171A patent/JP2019523283A/ja active Pending
- 2017-08-03 SG SG11201900665VA patent/SG11201900665VA/en unknown
- 2017-08-03 WO PCT/AU2017/050814 patent/WO2018023163A1/en unknown
- 2017-08-03 KR KR1020217002290A patent/KR20210013645A/ko not_active IP Right Cessation
- 2017-08-03 EP EP17836097.0A patent/EP3493798A4/en active Pending
- 2017-08-03 IL IL264461A patent/IL264461B1/en unknown
- 2017-08-03 MX MX2019001285A patent/MX2019001285A/es unknown
- 2017-08-03 PE PE2019000330A patent/PE20200726A1/es unknown
-
2018
- 2018-07-03 AU AU2018100923A patent/AU2018100923C4/en active Active
-
2019
- 2019-01-31 CL CL2019000270A patent/CL2019000270A1/es unknown
- 2019-02-01 CO CONC2019/0001044A patent/CO2019001044A2/es unknown
- 2019-10-23 AU AU2019253841A patent/AU2019253841B2/en active Active
-
2021
- 2021-10-01 AU AU2021240297A patent/AU2021240297B2/en active Active
-
2022
- 2022-07-14 US US17/865,024 patent/US11779562B2/en active Active
-
2023
- 2023-09-01 US US18/460,012 patent/US20230414559A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102869356A (zh) * | 2010-03-12 | 2013-01-09 | Gw药品有限公司 | 治疗癌症中的植物大麻素 |
WO2014145490A2 (en) * | 2013-03-15 | 2014-09-18 | Biotech Institute, Llc | Breeding, production, processing and use of specialty cannabis |
Also Published As
Publication number | Publication date |
---|---|
AU2018100923B4 (en) | 2018-09-27 |
AU2021240297A1 (en) | 2021-10-28 |
SG11201900665VA (en) | 2019-02-27 |
IL296008A (en) | 2022-10-01 |
KR20190035791A (ko) | 2019-04-03 |
MX2019001285A (es) | 2019-06-13 |
WO2018023163A1 (en) | 2018-02-08 |
US20220347155A1 (en) | 2022-11-03 |
BR112019001852A2 (pt) | 2019-05-07 |
EP3493798A1 (en) | 2019-06-12 |
CL2019000270A1 (es) | 2019-10-04 |
PE20200726A1 (es) | 2020-07-21 |
EP3493798A4 (en) | 2020-05-06 |
IL296008B1 (en) | 2024-05-01 |
CA3031810A1 (en) | 2018-02-08 |
US20230414559A1 (en) | 2023-12-28 |
AU2019253841B2 (en) | 2021-07-01 |
AU2018100923A4 (en) | 2018-08-09 |
AU2019253841A1 (en) | 2019-11-14 |
IL264461A (en) | 2019-02-28 |
AU2017307643B2 (en) | 2019-07-25 |
AU2021240297B2 (en) | 2023-08-24 |
JP2019523283A (ja) | 2019-08-22 |
AU2017307643A1 (en) | 2018-07-05 |
IL264461B1 (en) | 2024-05-01 |
AU2018100923C4 (en) | 2019-10-31 |
KR20210013645A (ko) | 2021-02-04 |
CO2019001044A2 (es) | 2019-04-30 |
US11779562B2 (en) | 2023-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109843287A (zh) | 大麻属组合物 | |
CN109789123A (zh) | 大麻属组合物 | |
CN109789124A (zh) | 大麻属组合物 | |
AU2018100837B4 (en) | Sleep Disorder Compositions and Treatments Thereof | |
US20230364052A1 (en) | Composition and method for treating autism | |
US20210308092A1 (en) | Cannabinoid composition and method for treating ptsd and/or anxiety | |
NZ789786A (en) | Sleep Disorder Compositions and Treatments Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190604 |